$CYTK News

Cytokinetics to Announce Third Quarter Results on November 4, 2026

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?

Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target

Cytokinetics Receives Notice Of Compliance From Health Canada Authorizing Treatment Use Of MYQORZO For Symptomatic Obstructive Hypertrophic Cardiomyopathy

William Blair Initiates Coverage On Cytokinetics with Outperform Rating

Here's How Much $1000 Invested In Cytokinetics 15 Years Ago Would Be Worth Today

Aficamten’s ACACIA-HCM Multi-Domain Gains Might Change The Case For Investing In Cytokinetics (CYTK)

Cytokinetics (CYTK), What Is Behind The Fresh Attention?

Cytokinetics (CYTK) Stock Looks Hard To Pin Down Following Strong Heart Drug Updates

Cytokinetics (CYTK) Reports Phase 3 Aficamten Gains In Non Obstructive HCM

Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026

Cytokinetics Presents Additional Data From Assessment Comparing Aficamten To Placebo On Cardiac Endpoints In Adults With Non-Obstructive HCM At HFSA Annual Scientific Meeting 2026

Cytokinetics Q2 2026 Earnings Call: Complete Transcript

RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $113

Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Begins ASPEN-HCM Study Evaluating MYQORZO In Adult Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference